Dr. Lennerz is one of the recipients of the 2018 Innovation Discovery Grant recipients and he leads the Breast Cancer Scanning Initiative (BCSI) aiming to predict unnecessary surgeries in high-risk breast lesions. Dr. Lennerz is board certified by the American Board of Pathology and the American Board of Medical Genetics. He joined the Massachusetts General Hospital Department of Pathology and Center for Integrated Diagnostics as a staff pathologist in 2014, and is an assistant professor at Harvard Medical School. Dr. Lennerz trained as a pathologist assistant in Berlin, Germany in 1994 and studied both medicine and molecular medicine at the University of Erlangen, Germany where he also received his MD and PhD. He completed his residency training in anatomic pathology in 2008, and a fellowship in molecular genetic pathology in 2009 at Washington University in St. Louis, MO. After completing a two-year gastrointestinal- and liver pathology fellowship at Massachusetts General Hospital in 2011, he led a research group on cancer biomarkers at Ulm University, Germany.
As the Associate Director of the Center for Integrated Diagnostics, Dr. Lennerz oversees the operational aspects of the clinical laboratory service that supports personalized medicine at the Massachusetts General Hospital. Dr. Lennerz focusses on assessment of new technologies – and specifically feasibility, demonstration of clinical utility and full integration into clinical practice to optimize care delivery including financial sustainability. Dr. Lennerz currently focusses on tissue-based biomarkers, digital pathology, applied machine-learning, and financial sustainability of molecular genetic diagnostics.